Rheumatology Advisor

ILD in RA More Likely in Older, Non-White Men and Is Linked to Worse Outcomes

RA-ILD has worse outcomes than RA and is most likely in those with extra-articular RA manifestations and in those who are ...
Seeking Alpha

Exclusive BAC Article: aTyr Pharma; Q3 Of 2025 Pulmonary Sarcoidosis Data Efzofitimod, Expansion Of SSc-ILD Interim Data, 2nd Half IND Filing ATYR0101 And Catalysts

aTyr Pharma is approaching a major inflection point with phase 3 EFZO-FIT topline results for efzofitimod in pulmonary sarcoidosis due Q3 2025. Positive interim phase 2 results in systemic ...
KXAN

VIDA Extends Trial Imaging Platform with the Addition of Data-Driven Texture Analysis (DTA) Fibrosis Score for ILD

In addition to the DTA Fibrosis Score, VIDA’s ILD offering enables the following trial services: • Enhanced eligibility assessments, supported by novel, patented visualizations, including Tomographic ...
Nasdaq

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally ...